Inner Retinal Layer Thinning in Parkinson Disease

Mohammedyusuf E. Hajee, MD; Wayne F. March, MD; Douglas R. Lazzaro, MD; Arthur H. Wolintz, MD; Eric M. Shrier, DO; Sofya Glazman, MD; Ivan G. Bodis-Wollner, MD, DSc

Objective: To quantify retinal thickness in patients with Parkinson disease (PD).

Methods: Forty-five eyes of 24 PD patients and 31 eyes of 17 control subjects underwent a comprehensive ophthalmologic examination. We used optical coherence tomography to examine retinal thickness, separately quantifying the inner and outer retinal layers. Intraocular pressure was measured by Goldmann applanation tonometry.

Results: The mean (SD) ages of the patients with PD and healthy subjects were 64.0 (6.5) years vs 63.5 (10.7) years (P = .77). The mean (SD) intraocular pressure was 13.6 (+/−2.7) mm Hg in the PD patients. No difference was found in either the superior or inferior outer retinal layer thickness of PD vs control eyes. The mean (SD) superior inner retinal layer thickness of PD vs control eyes was 88.79 (11.3) μm vs 103.5 (24.3) μm (P = .01), and the mean inferior inner retinal layer thickness was 89.83 (11.1) μm vs 104.0 (23.5) μm (P = .01).

Conclusions: The inner retinal layer is significantly thinner in PD patients than in healthy subjects. Idiopathic PD, distinct from glaucoma, needs to be considered in the differential diagnosis of retinal nerve fiber layer thinning.


Methods

Study Participants

Consecutive patients who were diagnosed as having idiopathic PD, based on the accepted UK Brain Bank criteria, were enrolled in the study by neurologists with a special interest in PD. Exclusion criteria were coincident posterior-pole disease, such as macular degeneration or any optic neuropathy due to glaucoma or ischemic optic neuropa-
that had stabilized their disease, whereas 11 had not yet been treated with dopaminergic agents (de novo patients). Of the treated PD patients, 7 were treated with presynaptic (levodopa) medications, 4 were taking a combination of levodopa and a dopamine receptor agonist, and 1 was taking pramipexole alone. Their disease stages ranged from 2 to 3, with a mean of 2.5.

EQUIPMENT AND MEASUREMENTS

We used Fourier-domain OCT (RTvue; Optovue, Inc; Fremont, California) with an imaging speed of approximately 25,000 axial scans per second, which is approximately 50 times faster than time-domain detection. One of the many advantages of this high speed is that it can allow the transformation from 2-dimensional to 3-dimensional imaging. The overall image quality of Fourier-domain OCT is also superior because of the elimination of many motion artifacts from the increased speed of acquisition. This is particularly relevant in PD patients with tremor. The axial resolution of a time-domain OCT is 8 to 10 µm, whereas for Fourier-domain OCT it is approximately 5 µm, which results in a more accurate representation of retinal topography.

Because a PD OCT protocol does not exist, the standard glaucoma protocol, which includes Nerve Head Map (NHM4) and Macula Map (MM7) scans (Optovue, Inc), was performed for all PD patients. The IRL includes the nerve fiber layer, the ganglion cell layer, and the inner-plexiform layer, whereas the ORL includes the layers starting from the inner nuclear layer up to and including the retinal pigment epithelium. The retinal layer measurements were 6 × 6-mm sections of the macula. Scans with artifacts such as motion and media were eliminated. Eyes of healthy (control) subjects were examined in the same way.

STATISTICAL ANALYSIS

Statistical analysis was performed using descriptive statistics and analyses of variance. To assess the reproducibility of data obtained with our instrument, we compared 2 consecutive OCT measurements in 7 healthy controls (13 eyes) in 1-week intervals. The mean IRL change was 1.25 µm. These data compare favorably with the stability data of Optovue, which claim an average variation of only 3 µm. The variability obtained with our equipment is comparable with results obtained with other equipment, such as Heidelberg retinal tomography devices.

RESULTS

In Figure 1 and Figure 2 we show the retina of a healthy individual and a patient with PD, respectively, who are roughly the same age. The paramacular area from where measurements were taken is indicated in millimeters.

INFERIOR AND SUPERIOR IRL THICKNESSES

The mean (SD) inferior IRL thickness of healthy eyes vs PD eyes was 104.0 (23.5) µm vs 88.79 (11.1) µm (P = .01). The mean superior IRL thickness of healthy eyes vs PD eyes was 103.5 (24.3) µm vs 89.83 (11.1) µm (P = .01). Clearly, the inferior and superior IRLs are similarly affected in PD patients, and the paramacular inner retina is approximately 15% thinner than the retina of PD patients in age-matched control subjects (Table).

Figure 1. The retina of a healthy individual. IRL indicates inner retinal layer; ORL, outer retinal layer.

Figure 2. The retina of a patient with Parkinson disease. IRL indicates inner retinal layer; ORL, outer retinal layer.

Table. The Retinal Thickness of Healthy Individuals vs Those of PD Patients

<table>
<thead>
<tr>
<th>Retinal Area</th>
<th>Retinal Thickness, µm</th>
<th>Healthy Individuals</th>
<th>PD Patients</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superior IRL</td>
<td>103.3 (24.3)</td>
<td>88.79 (11.3)</td>
<td>.01</td>
<td></td>
</tr>
<tr>
<td>Inferior IRL</td>
<td>104 (23.5)</td>
<td>89.83 (11.1)</td>
<td>.01</td>
<td></td>
</tr>
<tr>
<td>Superior ORL</td>
<td>170.2 (23.8)</td>
<td>170.4 (7.67)</td>
<td>.88</td>
<td></td>
</tr>
<tr>
<td>Inferior ORL</td>
<td>168.2 (22.9)</td>
<td>167.9 (7.86)</td>
<td>.99</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: IRL, inner retinal layer; ORL, outer retinal layer; PD, Parkinson disease. Data are presented as mean (SD).
ORL THICKNESS

The ORL thickness was also analyzed in the same manner as the IRL. The mean (SD) superior ORL thickness of healthy eyes vs PD eyes was 170.2 (+/-23.8) µm vs 170.4 (+/-7.67) µm (P=0.88). The mean (SD) inferior ORL thickness of healthy eyes vs PD eyes was 168.2 (+/-22.9) µm vs 167.9 (+/-7.86) µm (P=0.99). A factorial analysis of variance (general linear model) was used to examine if the difference between the right and left eye was dependent on PD diagnosis using the interaction between 2 factors: laterality (right, left eye) and PD diagnosis (PD, no PD). This interaction was not significant for either the superior or inferior IRL or ORL (Table).

INTEROCULAR COMPARISON OF IRL THICKNESS IN EARLY PD

Figure 3 illustrates a correlation between the left and right eyes of patients with relatively early PD. The corresponding statistics revealed a correlation coefficient of 0.82. Figure 4 shows a correlation between the left and right IRL thickness of patients with relatively early PD. The corresponding statistics revealed a correlation coefficient of 0.82.

CORRELATION BETWEEN MEAN IRL AND ORL IN EARLY PD

An insignificant correlation was also found between IRL and ORL thickness in the eyes of patients with relatively early PD. The corresponding statistics revealed a correlation coefficient of 0.33.

THE EFFECT OF TREATMENT

The mean (SD) superior nerve fiber layer thickness measurements of the treated eyes and untreated eyes were 87.0 (+/-11.17) µm and 91.05 (+/-7.14) µm (P=0.25), respectively. The mean (SD) inferior IRL thickness measurements of the treated eyes and untreated eyes were 89.51 (+/-9.52) µm and 91.04 (+/-8.12) µm (P=0.67), respectively. The mean (SD) superior ORL thickness measurements of the treated eyes and untreated eyes were 171.8 (+/-5.59) µm and 168.7 (+/-9.8 µm) (P=0.20), respectively. The mean (SD) inferior ORL thickness of the treated eyes and untreated eyes was 169.2 (+/-6.02) µm and 164.4 (+/-10.01) µm (P=0.45), respectively.

DISEASE DURATION AND IOP

The time elapsed from PD diagnosis compared with the severity of retinal findings was not statistically significant (P = .11). The mean (SD) IOP was 13.6 (+/-2.7) mm Hg in PD patients. The correlation of IOP to nerve fiber layer thickness was not statistically significant (r=0.26, P = .034).

COMMENT

Our study demonstrates a thinning of the IRL in the macular region in PD eyes. Inzelberg et al reported a stronger effect in the inferior peripapillary quadrant. Our results in PD suggest that the mean thickness of both superior and inferior macular hemispheres is roughly equal. However, looking at individual results, we found that 58% of the superior and 73% of the inferior IRL thickness of PD eyes fell outside 1 SD. When studying the same patients in 1.5 SDs, 47% of the superior PD IRL and 62% of inferior PD IRL fell outside the range. Clearly, a further comparison of inferior and superior IRL is needed for the paramacular region in a larger number of patients.

Recently, Altintas et al reported on the correlation of disease severity with inner foveal but without macular or peripapillary thickness in 17 PD eyes. We examined a 6-mm macular section, which correlates with 17° of central vision. The IRL contains both the ganglion and amacrine cell layers and is approximately 15% to 20% thinned in this region of the PD retina. Perhaps this modest loss is the reason for the absence of disc pallor in PD despite ganglion cell damage, a result also demonstrated by Yavas et al. However, the 15% to 20% loss in total IRL thickness does not necessarily cause a minor loss as far as vision is concerned.
Although visual acuity is only minimally affected in patients with well-corrected PD, they lose foveal CS to patterns to which healthy observers are most sensitive (need the least contrast to detect). However, levodopa treatment improves CS.\textsuperscript{24}

The PERG is a measure of retinal ganglion cell activity.\textsuperscript{25,26} In both PD and the monkey model, PERG shows a specific spatial frequency deficit\textsuperscript{12,13} similar to the spatial frequency selective CS loss in PD. Spatial frequency is one standard measure of the fineness or coarseness of the visual stimulus; it consists of alternating dark and bright bands (grating pattern). In healthy observers and monkeys, when PERG response or contrast sensitivity is plotted against spatial frequency, the resulting curve is nonmonotonic: it shows a peak that represents the best visible spatial frequency pattern. This is called spatial frequency tuning. Tuning reflects the interplay of antagonistic center or surround organization of foveal ganglion cell receptive fields.\textsuperscript{27} Tuning is attenuated or absent in CS or PERG in PD patients. On the basis of the effects of selective D\textsubscript{1} and D\textsubscript{2} receptor blockers on PERG of the monkey, we\textsuperscript{28,29} modeled the preganglionic dopaminergic circuit, which modulates the balance of center and surrounds the organization of foveal ganglion cells of the primate. The model quantifies the way that dopaminergic amacrine cells, although sparsely distributed, control the tuning of foveal ganglion cells via separate D\textsubscript{1}- and D\textsubscript{2}-linked receptors and the way that dopaminergic amacrine cell dysfunction may result in absent spatial frequency tuning.\textsuperscript{29}

Retinal thinning may be relevant to the early diagnosis and neuroprotective treatment of PD. Most of our patients were in the early stages of the disease. On the basis of the distribution of Lewy bodies at different stages of PD, Braak et al\textsuperscript{30} suggested that PD progresses from peripheral to central neurons in a caudocranial direction. It has not been investigated whether Lewy bodies are found in the human retina of PD patients. It needs to be established whether OCT measures contribute a quantitative measure to the early diagnosis of PD other than a constellation of early signs.\textsuperscript{31}

The OCT results in PD are potentially relevant for the ophthalmologist. The IRL thinning has been reported in other diseases, such as primary open-angle glaucoma,\textsuperscript{32} multiple sclerosis,\textsuperscript{33,34} and Alzheimer disease.\textsuperscript{35,36} The IOP is raised in glaucoma, whereas in our PD patients the IOP was normal. In Alzheimer disease retinal thinning is predominant only in the superior quadrant.\textsuperscript{35,36} In summary, Fourier-domain OCT may contribute a quantitative imaging approach to the early diagnosis, treatment, and follow-up of progression of PD.

\textbf{Submitted for Publication:} May 15, 2008; final revision received January 6, 2009; accepted January 15, 2009.

\textbf{Correspondence:} Ivan G. Bodis-Wollner, MD, DSc, Department of Ophthalmology and Department of Neurology, Parkinson's Disease and Related Disorders Center of Excellence, State University of New York—Downstate, 450 Clarkson Ave, Brooklyn, NY 11203 (ivan.bodis-wollner@downstate.edu).

\textbf{Financial Disclosure:} None reported.

\textbf{Funding/Support:} This study was funded by the National Parkinson Foundation. Dr Hajee was supported by an Empire Clinical Research Investigator Program—New York State Research Fellowship/Mentor Grant.

\textbf{Additional Contributions:} Hans Von Gizycki, PhD, provided statistical consultation. Zoya Belakovskaya, BS, and Mr. Alexander Belakovski provided technical support. Nancy Blace, MD, PhD, performed preliminary data collection. Muhammad Javaid, MD, assisted with graph preparations. Manuela E. Minko, MD, assisted in scheduling patients. Patricia Kavanagh, MD, referred and recruited patients. Hossam Attia, MD, performed a preliminary study comparing GDx Nerve Fiber Analyzer measures in patients with glaucoma and PD; he and Preeti Poley, MD, performed preliminary Glaucoma Diagnosis data collection.

\textbf{REFERENCES}


In 1795, Dr Isaac Thompson concocted an eye water of zinc sulfate, saffron, camphor, and rose water. It was sold as late as 1939. This is 1 of a series of 32 medical trade cards advertising the product from 1875 through 1895.

I

DR. ISAAC THOMPSON’S CELEBRATED EYE WATER, FOR ALL COMPLAINTS OF THE EYES. Each Bottle is stamped with my Proprietary Stamp. None other Genuine.

THE GENUINE EYE WATER

It is enclosed in an engraved envelope, on which is the likeness of the Original Inventor, DR. ISAAC THOMPSON, New London, Conn., with a facsimile of his signature; also the signature of JOHN L. THOMPSON, with a note of hand, signed by JOHN L. THOMPSON, 616 River Street, Troy, N. Y. None other can be Genuine.

This well-known and thoroughly efficient remedy has acquired a worldwide reputation, having been before the public for over eighty-five years, and it is a remarkable fact that its reputation has been sustained simply by the merits of the medicine, as the many thousands, who have used it, will bear testimony.

ITS MERITS STAND UNRIVALLED.
In constant use since 1795.
Price..........80 Cents per Bottle.

JOHN L. THOMPSON, Prop’t, Troy, N. Y.

 Courtesy of: Daniel M. Albert, MD, MS.

(Reprinted) Arch Ophthalmol/Vol. 127 (No. 6), June 2009 www.archophthalmol.com

©2009 American Medical Association. All rights reserved.

Downloaded From: by a Non-Human Traffic (NHT) User on 11/22/2018